目的 探討腎康栓聯(lián)合鹽酸貝那普利片治療糖尿病腎病的臨床療效。方法 選取2018年4月—2020年3月天津中醫(yī)藥大學(xué)第一附屬醫(yī)院收治的86例糖尿病腎病患者為研究對象，根據(jù)隨機(jī)數(shù)字表法將所有患者分為對照組和治療組，每組各43例。對照組口服鹽酸貝那普利片，10 mg/次，1次/d。治療組在對照組治療的基礎(chǔ)上給予腎康栓，每日早中晚各1粒，睡前2粒。兩組在治療8周后統(tǒng)計(jì)療效。觀察兩組的臨床療效，比較兩組腎功能指標(biāo)[白蛋白排泄率（UAER）、尿微量白蛋白、血清胱抑素C（Cys-C）]和細(xì)胞因子[內(nèi)皮素-1（ET-1）、單核細(xì)胞趨化因子-1（MCP-1）、降鈣素基因相關(guān)肽（CGRP）]水平。結(jié)果 治療后，治療組的總有效率（93.02%）高于對照組（79.07%），差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組的UAER、尿微量白蛋白、Cys-C水平均顯著低于治療前（P<0.05）；治療后，治療組的UAER、尿微量白蛋白、Cys-C水平比對照組低（P<0.05）。治療后，兩組的ET-1、MCP-1水平顯著降低，CGRP水平顯著升高（P<0.05）；治療后，治療組患者的ET-1、MCP-1水平比對照組低，CGRP水平比對照組高（P<0.05）。結(jié)論 腎康栓聯(lián)合鹽酸貝那普利片治療糖尿病腎病的療效確切，可改善腎功能，調(diào)節(jié)血清細(xì)胞因子水平，安全性良好，具有良好的臨床價(jià)值。

Objective To investigate the clinical effect of Shenkang Suppository combined with Benazepril Hydrochloride Tablets in treatment of diabetic nephropathy. Methods Patients (86 cases) with diabetic nephropathy in the First Teaching Hospital of Tianjin University of TCM from April 2018 to March 2020 were randomly divided into control and treatment groups, and each group had 43 cases. Patients in the control group were po administered with Benazepril Hydrochloride Tablets, 10 mg/time, once daily. Patients in the treatment group were given Shenkang Suppository on the basis of the control group, 1 grain in the morning, noon and evening, 2 grains before bed. Patients in two groups were treated for 8 weeks. After treatment, the clinical efficacies were evaluated, and renal function indexes (UAER, urinary microalbumin, and Cys-C) and cytokines (ET-1, MCP-1, and CGRP) in two groups were compared. Results The total effective rate of the treatment group was higher than that of the control group, and the difference was statistically significant (P<0.05). The levels of UAER, urinary microalbumin, and Cys-C in the two groups were significantly lower than those before treatment (P<0.05). After treatment, UAER, urinary microalbumin, and Cys-C in the treatment group were lower than those in the control group, the difference was statistically significant (P<0.05). After treatment, the levels of ET-1 and MCP-1 were significantly decreased, but the levels of CGRP were significantly increased (P<0.05). After treatment, the levels of ET-1 and MCP-1 in the treatment group were lower than those in the control group, but the levels of CGRP in the treatment group was higher than that in the control group, the difference was statistically significant (P<0.05). Conclusion Shenkang Suppository combined with Benazepril Hydrochloride Tablets has clinical curative effect in treatment of diabetic nephropathy, can improve renal function, regulate the level of serum cytokines, with good safety, which has good clinical value.

R977

國家自然科學(xué)基金資助項(xiàng)目（81373609）